USANA Health Sciences (NYSE:USNA) Issues FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 2.400-2.550 for the period, compared to the consensus EPS estimate of 2.780. The company issued revenue guidance of $850.0 million-$880.0 million, compared to the consensus revenue estimate of $883.5 million.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. DA Davidson reduced their target price on USANA Health Sciences from $46.00 to $38.00 and set a neutral rating on the stock in a report on Thursday. StockNews.com lowered USANA Health Sciences from a strong-buy rating to a buy rating in a research report on Wednesday.

USANA Health Sciences Price Performance

NYSE USNA traded up $0.17 on Friday, reaching $42.01. The stock had a trading volume of 3,070 shares, compared to its average volume of 79,800. The firm has a fifty day moving average of $46.27 and a two-hundred day moving average of $47.07. The company has a market cap of $800.29 million, a P/E ratio of 13.03, a price-to-earnings-growth ratio of 1.50 and a beta of 0.90. USANA Health Sciences has a 1-year low of $40.51 and a 1-year high of $68.00.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.11). USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The business had revenue of $212.87 million for the quarter, compared to the consensus estimate of $218.64 million. During the same quarter in the prior year, the company earned $0.89 earnings per share. Research analysts predict that USANA Health Sciences will post 2.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Myron W. Wentz sold 13,496 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $45.03, for a total transaction of $607,724.88. Following the completion of the sale, the insider now owns 7,864,345 shares of the company’s stock, valued at $354,131,455.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other USANA Health Sciences news, CFO G Doug Iiekking sold 5,198 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $44.76, for a total value of $232,662.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Myron W. Wentz sold 13,496 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $45.03, for a total value of $607,724.88. Following the completion of the sale, the insider now directly owns 7,864,345 shares of the company’s stock, valued at approximately $354,131,455.35. The disclosure for this sale can be found here. Insiders sold 31,591 shares of company stock valued at $1,458,098 over the last 90 days. Company insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.